OA10504A - Water-based topical cream containing nitroglycerinmethod of preparation and use thereof - Google Patents

Water-based topical cream containing nitroglycerinmethod of preparation and use thereof Download PDF

Info

Publication number: OA10504A
Authority: OA; OAPI
Prior art keywords: cream; daim; weight; water; treating
Prior art date: 1995-03-06

Application number

OA70069A

Other languages

English (en)

Inventor

Michael P Allen

Original Assignee

Internat Medical Innovations I

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-06

Filing date

1997-08-29

Publication date

2002-04-24

1997-08-29 Application filed by Internat Medical Innovations I filed Critical Internat Medical Innovations I

2002-04-24 Publication of OA10504A publication Critical patent/OA10504A/en

Links

XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 24
229940100611 topical cream Drugs 0.000 title claims abstract description 16
238000002360 preparation method Methods 0.000 title description 2
239000006071 cream Substances 0.000 claims abstract description 37
201000001881 impotence Diseases 0.000 claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 21
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims abstract description 18
239000000006 Nitroglycerin Substances 0.000 claims abstract description 16
229960003711 glyceryl trinitrate Drugs 0.000 claims abstract description 16
208000010228 Erectile Dysfunction Diseases 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
239000002562 thickening agent Substances 0.000 claims abstract description 10
201000010099 disease Diseases 0.000 claims abstract description 9
239000000203 mixture Substances 0.000 claims description 20
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
239000003623 enhancer Substances 0.000 claims description 10
239000003205 fragrance Substances 0.000 claims description 7
238000010438 heat treatment Methods 0.000 claims description 6
150000002148 esters Chemical class 0.000 claims description 5
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 5
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 3
208000002847 Surgical Wound Diseases 0.000 claims description 3
206010052428 Wound Diseases 0.000 claims description 3
208000027418 Wounds and injury Diseases 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
239000003086 colorant Substances 0.000 claims description 2
208000033808 peripheral neuropathy Diseases 0.000 claims description 2
229920000642 polymer Polymers 0.000 claims description 2
239000004094 surface-active agent Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 18
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
150000008064 anhydrides Chemical class 0.000 claims 1
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 1
239000003589 local anesthetic agent Substances 0.000 claims 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
208000037869 female anorgasmia Diseases 0.000 abstract description 7
239000003995 emulsifying agent Substances 0.000 abstract description 3
239000003961 penetration enhancing agent Substances 0.000 abstract 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
230000001568 sexual effect Effects 0.000 description 11
230000000699 topical effect Effects 0.000 description 10
-1 sédatives Substances 0.000 description 8
210000003029 clitoris Anatomy 0.000 description 7
239000000243 solution Substances 0.000 description 7
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 6
230000017531 blood circulation Effects 0.000 description 5
229910021538 borax Inorganic materials 0.000 description 5
229920000609 methyl cellulose Polymers 0.000 description 5
239000001923 methylcellulose Substances 0.000 description 5
235000010339 sodium tetraborate Nutrition 0.000 description 5
BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
239000002550 vasoactive agent Substances 0.000 description 4
206010002652 Anorgasmia Diseases 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 3
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 2
206010053317 Hydrophobia Diseases 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
229920002675 Polyoxyl Polymers 0.000 description 2
208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 2
201000001880 Sexual dysfunction Diseases 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000002220 antihypertensive agent Substances 0.000 description 2
229940030600 antihypertensive agent Drugs 0.000 description 2
230000037007 arousal Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001856 erectile effect Effects 0.000 description 2
208000003532 hypothyroidism Diseases 0.000 description 2
230000002989 hypothyroidism Effects 0.000 description 2
238000009802 hysterectomy Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
229960003639 laurocapram Drugs 0.000 description 2
229960004194 lidocaine Drugs 0.000 description 2
238000007726 management method Methods 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
238000011471 prostatectomy Methods 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
230000002792 vascular Effects 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
UHBVTTDRNVAOJD-UHFFFAOYSA-N 1-nitropropane-1,2,3-triol Chemical compound OCC(O)C(O)[N+]([O-])=O UHBVTTDRNVAOJD-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010021067 Hypopituitarism Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000002364 Leriche syndrome Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010046914 Vaginal infection Diseases 0.000 description 1
201000008100 Vaginitis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000032683 aging Effects 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
150000005215 alkyl ethers Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
201000001962 aortic atherosclerosis Diseases 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
235000021170 buffet Nutrition 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
229960001747 cinchocaine Drugs 0.000 description 1
PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
210000005226 corpus cavernosum Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000006159 dianhydride group Chemical group 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000003387 muscular Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001272 neurogenic effect Effects 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002674 ointment Substances 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000035807 sensation Effects 0.000 description 1
230000036332 sexual response Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
150000003462 sulfoxides Chemical class 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
229940124549 vasodilator Drugs 0.000 description 1
239000003071 vasodilator agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA70069A 1995-03-06 1997-08-29 Water-based topical cream containing nitroglycerinmethod of preparation and use thereof OA10504A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US39887295A	1995-03-06	1995-03-06
US08/594,304 US5698589A (en)	1993-06-01	1996-01-30	Water-based topical cream containing nitroglycerin and method of preparation and use thereof

Publications (1)

Publication Number	Publication Date
OA10504A true OA10504A (en)	2002-04-24

Family

ID=27016409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA70069A OA10504A (en)	1995-03-06	1997-08-29	Water-based topical cream containing nitroglycerinmethod of preparation and use thereof

Country Status (21)

Country	Link
US (1)	US5698589A (de)
EP (1)	EP0814800B1 (de)
JP (1)	JPH11501629A (de)
KR (1)	KR19980702766A (de)
CN (1)	CN1139380C (de)
AP (1)	AP691A (de)
AT (1)	ATE209895T1 (de)
AU (1)	AU701328B2 (de)
BR (1)	BR9607974A (de)
CZ (1)	CZ281897A3 (de)
DE (1)	DE69617654T2 (de)
EA (1)	EA000566B1 (de)
HU (1)	HUP9801234A3 (de)
NO (1)	NO974075L (de)
NZ (1)	NZ305095A (de)
OA (1)	OA10504A (de)
PL (1)	PL322110A1 (de)
SI (1)	SI9620038A (de)
SK (1)	SK117597A3 (de)
TR (1)	TR199700909T1 (de)
WO (1)	WO1996027372A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5698589A (en) *	1993-06-01	1997-12-16	International Medical Innovations, Inc.	Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US6143746A (en) *	1994-01-21	2000-11-07	Icos Corporation	Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20020143007A1 (en) *	1996-02-02	2002-10-03	Garvey David S.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US20050065161A1 (en) *	1996-02-02	2005-03-24	Nitromed, Inc.	Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en)	1996-02-02	2002-10-22	Nitromed, Inc.	Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6294517B1 (en)	1996-02-02	2001-09-25	Nitromed, Inc.	Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US6323211B1 (en)	1996-02-02	2001-11-27	Nitromed, Inc.	Compositions and methods for treating sexual dysfunctions
USRE37234E1 (en) *	1996-11-01	2001-06-19	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5958926A (en)	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en)	1996-11-01	2001-12-18	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
GB2325855B (en) *	1997-06-04	2001-08-29	Healthscene Ltd	Preparation for topical application to the male sexual organ
EP1535611A3 (de) *	1997-06-23	2009-09-16	Strakan International Limited	Microdosistherapie von Gefässbedingten Erscheinungen durch NO-Donoren
AU756136B2 (en) *	1997-06-23	2003-01-02	Queen's University At Kingston	Microdose therapy
US6103765A (en)	1997-07-09	2000-08-15	Androsolutions, Inc.	Methods for treating male erectile dysfunction
CA2295595A1 (en)	1997-07-09	1999-01-21	Androsolutions, Inc.	Improved methods and compositions for treating male erectile dysfunction
US6593369B2 (en)	1997-10-20	2003-07-15	Vivus, Inc.	Methods, compositions, and kits for enhancing female sexual desire and responsiveness
CA2306837C (en)	1997-10-28	2007-05-08	Vivus, Inc.	Treatment of female sexual dysfunction
US20040014761A1 (en) *	1997-10-28	2004-01-22	Place Virgil A.	Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20050070516A1 (en) *	1997-10-28	2005-03-31	Vivus Inc.	As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6472425B1 (en)	1997-10-31	2002-10-29	Nitromed, Inc.	Methods for treating female sexual dysfunctions
GB9802078D0 (en) *	1998-01-30	1998-03-25	Futura Medical Limited	Preparation for treatment of erectile dysfunction
WO1999062533A1 (en) *	1998-06-04	1999-12-09	Jedco Products, Llc	Preparation for topical application to the male sexual organ
US7087240B1 (en)	1998-06-25	2006-08-08	Lavipharm Laboratories Inc.	Device and method for the treatment of erectile dysfunction
GB9818524D0 (en) *	1998-08-25	1998-10-21	Futura Medical Limited	Inorgasmia treatment
IT1303793B1 (it) *	1998-11-27	2001-02-23	Promefarm S R L	"composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
US6486207B2 (en)	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en)	1998-12-10	2004-11-30	Nexmed (Holdings) , Inc.	Compositions and methods for amelioration of human female sexual dysfunction
DE60131644T2 (de) *	2000-05-09	2008-10-30	Nitromed, Inc., Lexington	Infrarotthermographie und behandlung von sexuellen dysfunktionen
KR100452972B1 (ko)	2000-05-16	2004-10-14	주식회사 삼양사	경피투여용 하이드로젤 조성물
US6737084B2 (en)	2000-06-27	2004-05-18	Qualilife	Compositions and methods for enhancing or treating female sexual response
HUP0002628A2 (en) *	2000-07-14	2002-06-29	Keri Pharma Kft	Pharmaceutical combinations for treating diabetes
ES2341090T3 (es) *	2000-08-30	2010-06-15	Unimed Pharmaceuticals, Llc	Procedimiento para tratar la disfuncion erectil y aumentar la libido en hombres.
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) *	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
WO2002069906A2 (en) *	2001-03-06	2002-09-12	Cellegy Pharmaceuticals, Inc.	Compounds and methods for the treatment of urogenital disorders
JP2003040763A (ja) *	2001-05-23	2003-02-13	Taisho Pharmaceut Co Ltd	多価アルコール含有軟膏剤基剤
SE0103528D0 (sv) *	2001-10-21	2001-10-21	Jan Faergeman	Topiska kompositioner med förstärkt effekt
MXPA04007828A (es) *	2002-02-15	2004-10-15	Nexmed Holdings Inc	Composicion de prostaglandina para eltratamiento de la disfuncion erectil.
IL163981A0 (en) *	2002-03-15	2005-12-18	Unimed Pharmaceuticals Inc	Androgen pharmaceutical composition and method fortreating depression
HU230920B1 (hu) *	2002-03-15	2019-03-28	Besins Healthcare Luxembourg Sarl	Depresszió kezelésére szolgáló androgén gyógyászati készítmények
US8012472B2 (en) *	2002-12-23	2011-09-06	William Marsh Rice University	Compositions and methods for suppressing fibrocytes
US7763256B2 (en) *	2002-12-23	2010-07-27	William Marsh Rice University	Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
US20100297074A1 (en) *	2002-12-23	2010-11-25	Richard Hans Gomer	Wound healing compositions, systems, and methods
PT1596880E (pt) *	2002-12-23	2011-06-06	Univ Rice William M	Métodos e composições para suprimir a diferenciação de fibrócitos
US20050031699A1 (en)	2003-06-26	2005-02-10	L'oreal	Porous particles loaded with cosmetically or pharmaceutically active compounds
GB0417675D0 (en) *	2004-08-09	2004-09-08	Futura Medical Dev Ltd	Composition for promoting vascular smooth muscle relaxation
US20060078580A1 (en) *	2004-10-08	2006-04-13	Mediquest Therapeutics, Inc.	Organo-gel formulations for therapeutic applications
US7740875B2 (en) *	2004-10-08	2010-06-22	Mediquest Therapeutics, Inc.	Organo-gel formulations for therapeutic applications
JP2008520694A (ja) *	2004-11-17	2008-06-19	リンジー・バークソン	非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法
US20060127483A1 (en) *	2004-12-10	2006-06-15	Alan Drizen	Topical drug delivery system
GB0602224D0 (en) *	2006-02-03	2006-03-15	Futura Medical Dev Ltd	Composition for promoting vascular smooth muscle relaxation
ES2409756T3 (es) *	2006-12-04	2013-06-27	Promedior, Inc.	Combinación de SAP y de enalapril para su uso en tratamiento de trastornos fibróticos o fibroproliferativos
US9884899B2 (en)	2007-07-06	2018-02-06	Promedior, Inc.	Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) *	2007-07-06	2013-07-30	Promedior, Inc.	Methods and compositions useful in the treatment of mucositis
HU227970B1 (en) *	2007-07-10	2012-07-30	Egis Gyogyszergyar Nyrt	Pharmaceutical compositions containing silicones of high volatility
DE202008007318U1 (de) *	2008-03-14	2008-07-31	G. Pohl-Boskamp Gmbh & Co. Kg	Langzeitstabile pharmazeutische Zubereitung mit dem Wirkstoff Glyceroltrinitrat
US20100263675A1 (en) *	2009-04-21	2010-10-21	Ansell Healthcare Products Llc	Condom with Localized Active Agent
WO2009152071A1 (en) *	2008-06-09	2009-12-17	Vanderbilt University	Unnatural dispyrin analogues, preparation and uses thereof
US20100016446A1 (en) *	2008-07-21	2010-01-21	Sylvia Gonda	Stable water-based topical pharmaceutical creams and methods of making and using same
WO2010057117A2 (en) *	2008-11-14	2010-05-20	Helm Pharmaceuticals, Inc.	Topical transdermal drug delivery compositions
CA2754961C (en) *	2009-03-11	2018-04-10	Promedior, Inc.	Treatment and diagnostic methods for hypersensitive disorders
EP2405929B1 (de) *	2009-03-11	2018-06-06	Promedior Inc.	Ein sap polypeptid zur verwendung in der behandlung von autoimmunerkrankungen und graft vers host reaktion
UA110323C2 (en) *	2009-06-04	2015-12-25	Promedior Inc	Derivative of serum amyloid p and their receipt and application
EP2987803B1 (de) *	2009-06-17	2018-08-29	Promedior Inc.	Sap-varianten und deren verwendung
WO2011057386A1 (en) *	2009-11-13	2011-05-19	Oral Delivery Technology Ltd.	Composition and prophylactic device for enhancing sexual performance or pleasure
ES2582309T3 (es) *	2010-08-03	2016-09-12	G. Pohl-Boskamp Gmbh & Co. Kg	Uso de trinitrato de glicerilo para el tratamiento de edema traumático
WO2012113564A1 (en)	2011-02-25	2012-08-30	G. Pohl-Boskamp Gmbh & Co. Kg	Stabilized granules containing glyceryl trinitrate
US9248099B2 (en)	2012-05-31	2016-02-02	Desmoid Aktiengesellschaft	Use of stabilized granules containing glyceryl trinitrate for arteriogenesis
PL2668947T3 (pl)	2012-05-31	2017-06-30	G. Pohl-Boskamp Gmbh & Co. Kg	Indukcja arteriogenezy donorem NO, takim jak nitrogliceryna
US11154535B2 (en)	2012-07-31	2021-10-26	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US10045965B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US10045935B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
EP2878310B1 (de)	2013-11-29	2017-01-11	G. Pohl-Boskamp GmbH & Co. KG	Sprühbare wässrige Zusammensetzung mit Nitroglycerin
JP2021506958A (ja)	2017-12-13	2021-02-22	オンクォリティファーマシューティカルズチャイナエルティーディーＯｎｑｕａｌｉｔｙＰｈａｒｍａｃｅｕｔｉｃａｌｓＣｈｉｎａＬｔｄ．	Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
KR102831159B1 (ko)	2018-04-16	2025-07-07	온퀄리티 파마슈티컬스 차이나 리미티드	암 치료의 부작용을 예방하거나 치료하기 위한 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1163561A (en) *	1979-11-06	1984-03-13	Cyril Boroda	Preparation containing nitroglycerine and optionally other medicaments and preparation thereof
US4336243A (en) *	1980-08-11	1982-06-22	G. D. Searle & Co.	Transdermal nitroglycerin pad
US4521421A (en) *	1983-09-26	1985-06-04	Eli Lilly And Company	Treatment of sexual dysfunction
US5204339A (en) *	1986-01-31	1993-04-20	Whitby Research, Inc.	Penetration enhancers for transdermal delivery of systemic agents
US4801587A (en) *	1987-03-02	1989-01-31	Gene Voss	Impotence ointment
US5001151A (en) *	1987-08-11	1991-03-19	Fujisawa Usa, Inc.	Aqueous nitroglycerin injection and manufacturing process
US5256652A (en) *	1987-11-12	1993-10-26	Pharmedic Co.	Topical compositions and methods for treatment of male impotence
SE463851B (sv) *	1988-09-02	1991-02-04	Amsu Ltd	Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) *	1989-06-12	1991-10-22	Centuries Laboratories, Inc.	Method and composition for treating impotence
US5262165A (en) *	1992-02-04	1993-11-16	Schering Corporation	Transdermal nitroglycerin patch with penetration enhancers
US5242391A (en) *	1990-04-25	1993-09-07	Alza Corporation	Urethral insert for treatment of erectile dysfunction
US5698589A (en) *	1993-06-01	1997-12-16	International Medical Innovations, Inc.	Water-based topical cream containing nitroglycerin and method of preparation and use thereof

1996
- 1996-01-30 US US08/594,304 patent/US5698589A/en not_active Expired - Lifetime
- 1996-03-05 AT AT96909577T patent/ATE209895T1/de not_active IP Right Cessation
- 1996-03-05 EA EA199700213A patent/EA000566B1/ru not_active IP Right Cessation
- 1996-03-05 KR KR1019970706173A patent/KR19980702766A/ko not_active Ceased
- 1996-03-05 BR BR9607974A patent/BR9607974A/pt not_active Application Discontinuation
- 1996-03-05 AU AU53025/96A patent/AU701328B2/en not_active Ceased
- 1996-03-05 TR TR97/00909T patent/TR199700909T1/xx unknown
- 1996-03-05 PL PL96322110A patent/PL322110A1/xx unknown
- 1996-03-05 DE DE69617654T patent/DE69617654T2/de not_active Expired - Lifetime
- 1996-03-05 CZ CZ972818A patent/CZ281897A3/cs unknown
- 1996-03-05 WO PCT/US1996/002989 patent/WO1996027372A1/en not_active Ceased
- 1996-03-05 NZ NZ305095A patent/NZ305095A/en not_active IP Right Cessation
- 1996-03-05 HU HU9801234A patent/HUP9801234A3/hu unknown
- 1996-03-05 EP EP96909577A patent/EP0814800B1/de not_active Expired - Lifetime
- 1996-03-05 SK SK1175-97A patent/SK117597A3/sk unknown
- 1996-03-05 AP APAP/P/1997/001068A patent/AP691A/en active
- 1996-03-05 JP JP8527007A patent/JPH11501629A/ja active Pending
- 1996-03-05 CN CNB961922737A patent/CN1139380C/zh not_active Expired - Fee Related
- 1996-03-05 SI SI9620038A patent/SI9620038A/sl unknown
1997
- 1997-08-29 OA OA70069A patent/OA10504A/en unknown
- 1997-09-04 NO NO974075A patent/NO974075L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP0814800A1 (de)	1998-01-07
CN1139380C (zh)	2004-02-25
ATE209895T1 (de)	2001-12-15
JPH11501629A (ja)	1999-02-09
CN1177294A (zh)	1998-03-25
AU5302596A (en)	1996-09-23
DE69617654D1 (de)	2002-01-17
CZ281897A3 (en)	1997-12-17
NO974075L (no)	1997-10-27
SI9620038A (sl)	1998-04-30
NO974075D0 (no)	1997-09-04
EP0814800A4 (de)	1998-07-01
AP9701068A0 (en)	1997-10-31
PL322110A1 (en)	1998-01-05
HK1005359A1 (en)	1999-01-08
BR9607974A (pt)	1998-01-13
HUP9801234A3 (en)	2000-07-28
KR19980702766A (ko)	1998-08-05
DE69617654T2 (de)	2002-08-08
US5698589A (en)	1997-12-16
EA199700213A1 (ru)	1998-02-26
AU701328B2 (en)	1999-01-28
HUP9801234A2 (hu)	1999-01-28
EA000566B1 (ru)	1999-12-29
NZ305095A (en)	2005-05-27
EP0814800B1 (de)	2001-12-05
AP691A (en)	1998-10-12
SK117597A3 (en)	1998-01-14
WO1996027372A1 (en)	1996-09-12
TR199700909T1 (xx)	1998-02-21

Publication	Publication Date	Title
OA10504A (en)	2002-04-24	Water-based topical cream containing nitroglycerinmethod of preparation and use thereof
Gajraj et al.	1994	Eutectic mixture of local anesthetics (EMLA®) cream
FI102454B (fi)	1998-12-15	Menetelmä erektiilisen dysfunktion hoitamiseksi käytettävän koostumuks en valmistamiseksi
KR20010022296A (ko)	2001-03-15	음경 발기 부전증 치료용 조성물 및 치료 방법
US6589990B1 (en)	2003-07-08	Methods and compositions for misoprostol compound treatment of erectile dysfunction
MXPA02006758A (es)	2008-09-12	Composicion de prostaglandinas y metodos de tratamiento de la disfuncion erectil masculina.
WO1999038472A2 (en)	1999-08-05	Topical vasodilatory gel composition and methods of use and production
CA2314369A1 (en)	1999-06-24	Prostaglandin e2/f2.alpha. combination for treating impotence and enhancing sexual arousal
EP1049461B1 (de)	2002-01-09	Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
WO1996031204A1 (en)	1996-10-10	Compositions and process for treating hemangioma
CA2214418C (en)	2006-10-10	Water-based topical cream containing nitroglycerin; method of preparation and use thereof
US6897239B1 (en)	2005-05-24	Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women
US20060127483A1 (en)	2006-06-15	Topical drug delivery system
WO2024158098A1 (ko)	2024-08-02	남성 성기의 일시적 굵기 확대 및 혈행 개선과 사정을 지연시키는 피부 외용제 조성물
HK1005359B (en)	2004-12-24	Water-based topical cream containing nitroglycerin; method of preparation and use thereof
TW200526229A (en)	2005-08-16	External preparation for treating sexual dysfunction
WO2000010559A1 (en)	2000-03-02	Inorgasmia treatment
HK1033647B (en)	2002-09-06	Preparation for treatment of erectile dysfunction